EyRIS aims to transfigure the delivery of healthcare through AI-powered solutions, with the ultimate goal of being the game changer in the future of first-stage medical diagnostics. Its foray into the healthcare industry focuses on the development and commercialisation of innovative products to revolutionise the detection of retinal and chronic diseases in our communities.
Our flagship product, SELENA+, is an AI that is capable of detecting three retinal diseases, diabetic retinopathy, glaucoma suspect and age-related macular degeneration. SELENA+ has transcended significant geographical barriers by establishing its presence in 26 countries today, a feat that required careful navigation around various international regulatory approvals.
SELENA+ is an Artificial Intelligence (AI) Deep Learning System (DLS) that involved the synergy of research and expertise between the Singapore Eye Research Institute (SERI) and the National University of Singapore (NUS). Using Convolutional Neural Networks, SELENA+ automatically grades fundus images and detects eye diseases such as Diabetic Retinopathy, Glaucoma and Age-Related Macular Degeneration to limit the effects of preventable blindness.
It assesses images of the retina taken using a fundus camera to generate a report that highlights urgent cases requiring specialist referrals. SELENA+ has been deployed in 22 countries, and sights are now set on the China and US markets among many others. Beyond international expansion, EyRIS’ next steps involve developing new verticals that can detect other conditions such as chronic kidney disease, stroke and cardiovascular diseases.